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Our conception of the human genome, long focused on the 2% that codes for
proteins, has profoundly changed since its first draft assembly in 2001. Since then,
an unanticipatedly expansive functionality and convolution has been attributed to the
majority of the genome that is transcribed in a cell-type/context-specific manner
into transcripts with no apparent protein coding ability. While the majority of these
transcripts, currently annotated as long non-coding RNAs (lncRNAs), are functionally
uncharacterized, their prominent role in embryonic development and tissue homeostasis,
especially in the context of the heart, is emerging. In this review, we summarize and
discuss the latest advances in understanding the relevance of lncRNAs in (re)building the
heart.
Keywords: long non-coding RNAs, embryonic development, homeostasis, cardiac development, cardiac
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“His very existence was improbable, inexplicable, and altogether bewildering. He was an insoluble problem.
It was inconceivable how he had existed, how he had succeeded in getting so far, how he had managed to
remain – why he did not instantly disappear.”
—Joseph Conrad, Heart of Darkness.
Over the last 20 years, the advent of novel sequencing technologies and initiatives such as
ENCODE have revealed that the majority of the mammalian genome, despite not being translated
into proteins, is pervasively transcribed into myriad RNAs of different sizes and characteristics,
collectively referred to as non-coding RNAs (ncRNAs). To date, thousands of ncRNAs have been
described in humans, yet the precise functional roles of a great majority remain unclear and
controversial. Non-coding RNAs are traditionally classified based on their size into two major
classes, small non-coding RNAs and long non-coding (lnc) RNAs. Small non-coding RNAs were
first described in 1993 (Lee et al., 1993), and have been studied extensively since then, along with
their molecular mechanisms of action and function. Although much is left to be learnt from them
(e.g., piRNAs) they are outside the scope of this review, but readers can consult the excellent reviews
(Bartel, 2004, 2009; Carthew and Sontheimer, 2009;Malone andHannon, 2009;Mendell andOlson,
2012).
Long non-coding RNAs are defined as a large and diverse group of non-protein coding
transcripts longer than 200 nucleotides (Rinn and Chang, 2012). Currently, they represent one
of the most prominent but least understood genes in vertebrates. Overall, more than ∼100,000
genomic loci are predicted to produce lncRNAs in the human genome (Zhao et al., 2016)
and account for the largest class of genes, giving an idea of the potential relevance of this
class of molecules. The consistent observation of cell type/tissue specific expression, together
with their increased presence in evolutionarily more complex organisms, lncRNAs have been
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proposed to play key roles in affecting diverse cellular functions
from modulating chromatin states to protein synthesis.
Ultimately, this imparts a new layer of sophistication to the
control of fundamental biological processes. In line with
this, their roles in health and disease, including embryonic
development, homeostasis, cancer, neurodegenerative, and
metabolic disorders are rapidly becoming clear.
As evident from the exponentially increasing body of
literature, lncRNAs are particularly interesting in the context
of cardiac biology. The hierarchy and ontogeny of cardiac
specification is becoming increasingly complex with the
identification of primary, secondary [and potentially tertiary
(Bressan et al., 2013)] heart fields that together give rise to the
multitude of highly specialized cell types that constitute the
mammalian heart [for review, see (Buckingham et al., 2005;
Brade et al., 2013)]. Among multiple modes of gene regulation
that fine tune cardiac development, recent studies reveal a
prominent role for lncRNAs (Grote et al., 2013; Klattenhoff
et al., 2013; Ounzain et al., 2014, 2015a,b; Kurian et al., 2015).
Additionally, dysregulated lncRNAs have been implicated in
cardiovascular diseases (Yap et al., 2010; Han et al., 2014;
Michalik et al., 2014; Ounzain et al., 2014, 2015a,b; Wang
et al., 2014a,b; Yan et al., 2015), including coronary artery and
other heart dysfunctions, which remain the leading cause of
mortality in the developed world, ahead of all cancer types
combined. In the United States alone, 80 million people suffer
from cardiovascular disorders, and cardiovascular diseases
are projected to be the leading cause of death in the world by
2020, highlighting the importance of a better understanding of
their etiology. Cardiac injuries, such as myocardial infarction
(MI), usually caused by an occlusion of a coronary artery,
can lead to immediate death due to the loss of oxygenation in
the ventricular muscle. Such an occlusion quickly results in
ischemia/reperfusion injury and necrosis of the tissue. Patients
who survive a cardiac episode face progressive deterioration
due to compensatory responses over several years, resulting in
heart failure and eventually death. Although the molecular and
cellular mechanisms involved in these pathologic responses are
now better understood, many puzzles remain to be solved and
the treatment of cardiac disorders remains poor. Investigating
the regulatory functions of lncRNAs in cardiac homeostasis and
disease might open new avenues in the treatment of cardiac
disorders. In this review, we will summarize the latest progress in
understanding the molecular mechanisms of lncRNA function
in cardiac biology and their potential as novel therapeutic targets
in the future.
EVOLUTION OF THE LNCRNA
PARADIGM—FROM JUNK TO ROSETTA
STONE
The study of lncRNAs originates from the interest in the
non-protein coding (hereafter termed non-coding) part of the
genome, its evolution and its potential function in the 1950s.
Scientists quickly discovered the C-value paradox, that is, the
lack of correlation between organismal size or developmental
complexity and the DNA content of a cell. Lower animals—
from an anthropocentric perspective—such as salamanders and
fish, can have a genome many times larger than higher order
organisms, such as humans. The paradox seemed solved when
it was found that most of the genome does not encode for
protein-coding genes (Ohno, 1972). The non-coding portion of
the genome was prematurely termed “junk DNA” due to the
high presence of transposons, pseudogenes, repeats, and other
elements of dubious or unknown function. Interestingly, this part
of the genome accounts for 50–70% of the mammalian genome
(de Koning et al., 2011). However, even then geneticists were
still puzzled by the C-paradox. Although a part of the non-
coding genome accounted for structural regions in the DNA,
the majority remained unexplained. So the question remained:
why would organisms maintain such a large genome—at high
energy cost—without having any major function? Indeed, many
of the early pioneers suspected something more was at stake and
expressed their belief that the non-coding genome might not be
entirely useless.
The first evidence for the potential function of the non-
coding part of the genome was that the transcriptional activity
in cells was too high to be entirely attributable to coding
genes and ribosomal RNAs. Heterogeneous nuclear RNAs were
soon discovered as RNAs originating from repetitive and
heterochromatic regions with no protein-coding ability (Yunis
and Tsai, 1978). Some years later, more non-coding RNAs
involved in post-transcriptional regulation were found, including
snRNAs and snoRNAs. However, it was not until the advent of
microarrays and next-generation sequencing methodologies in
the last decades that our picture of non-coding RNAs became
more complete. The scale of pervasive transcription is much
larger than previously appreciated, with estimates ranging from
70 to 90% of the human genome being transcribed at one point
or another during development, homeostasis or disease (Bertone
et al., 2004; Mercer and Mattick, 2013). Some of these transcripts
are present at very low copy numbers and controversy still
exists on their actual relevance. Indeed, a number of putative
lncRNA transcripts might be the effect of pervasive transcription
and transcriptional “noise.” However, detailed RNA-sequencing
analysis and chromatin signatures (histone modifications, TF
binding, DNase I hypersensitivity assays) indicate strong control
of regulatory elements in these loci, suggesting that a significant
percentage of lncRNA transcripts indeed constitute novel non-
coding genes with currently unknown function (Guttman et al.,
2009; Cabili et al., 2011; Iyer et al., 2015). It would seem now that
ncRNAs play more important roles than anticipated and might
constitute a “Rosetta Stone,” a new layer of gene regulation that
might offer insight into the complexity of higher organisms.
CLASSES OF LNCRNAS AND THEIR
GENOMIC ARCHITECTURE
Being defined solely by size and a lack of coding potential,
lncRNAs constitute a large and heterogeneous group of RNA
molecules. It is therefore not surprising that their genomic
contexts show a similar variability (Figure 1A; Cabili et al., 2011).
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FIGURE 1 | Genomic contexts of lncRNAs & modes of action. (A) LncRNA genes (blue) can exist in various genomic contexts. The histone marks are similar to
protein-coding genes. NcRNAs transcribed from enhancer regions are unique in their features. (B) Overview of the different interactions of lncRNAs and their target
molecules.
Strikingly, a large fraction of lncRNA loci and transcripts show
strong similarities to protein-coding transcripts with regards
to histone marks occupying their promoters and gene body,
intron-exon structure and poly-adenylation. Based on their
genomic architecture, lncRNAs are categorized as long intergenic
non-coding RNAs (lincRNAs), antisense lncRNAs, intronic
lncRNAs, circular RNAs, divergent lncRNAs, and enhancer
RNAs. A major class of lncRNAs, long intergenic non-coding
RNAs (lincRNAs), is located in barren gene deserts or between
two protein-coding genes. This particular class operates as
stand-alone genes, often having their own regulatory landscape.
Another class of lncRNAs, intronic lncRNAs, is located within
introns of protein-coding genes similar to what has been reported
for many microRNAs. Antisense lncRNAs are transcribed from
the opposite strand of a protein-coding RNA. They can also
exist outside the gene body of their associated coding gene,
resulting in various degrees of transcriptional overlap, ranging
from short stretches to a complete overlap. A different form
of antisense transcripts is divergent lncRNAs. These genes are
controlled by the same promoter region as the coding neighbor,
but are transcribed in the opposite direction to the coding gene,
without any transcriptional overlap. The function of this class
of lncRNAs is very poorly understood. In contrast, enhancer
RNA (eRNA) and circular RNAs (ciRNAs) are uniquely distinct
in their genomic architecture. eRNAs are transcribed by active
enhancers and are often single exonic and not poly-adenylated.
Furthermore, during active transcription the gene body is not
marked by H3K3me3, but H3K4 monomethylation and H3K27
acetylation in combination with abundant binding of the p300
co-activator (De Santa et al., 2010; Kim et al., 2010). The function
of eRNA transcripts currently remains controversial. Recently,
a novel class of lncRNAs arising from circularization of exons
has been described (Zhang et al., 2013). Interestingly these
circular RNAs (ciRNAs) can emerge from protein-coding genes
by covalently linking separate exons.
MOLECULAR MECHANISMS OF
LNCRNA-MEDIATED GENE REGULATION
Similar to the diverse genomic contexts in which lncRNA genes
can be found, lncRNAs can exert their regulatory function
through a wide variety of mechanisms (Figure 1B). In contrast
to the well-studied microRNAs, lncRNAs are not limited to
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interactions with other transcripts, but can exert their function
along with proteins, RNAs and DNA, thereby expanding the
dimensions by which they can operate. When interacting
with proteins, lncRNAs can act as guides for targeting a
protein/protein complex to specific sites/subcellular locations
(Rinn et al., 2007; Yap et al., 2010; Grote et al., 2013), as scaffolds
to bring different subunits of protein complexes together and
maintain them in close proximity (Wang et al., 2004; Tsai et al.,
2010; Yang et al., 2011) or act as decoys to sequester proteins
away from their site of action (Kino et al., 2010; Tripathi
et al., 2010; Hung et al., 2011). In the context of the heart,
lncRNA Myheart (Mhrt) directly binds to Brg1 in order to
inhibit its helicase function (Han et al., 2014). Similarly, lncRNAs
carrying repeats of corresponding complimentary sequences to
miRNAs can sequester them acting as miRNA sponges [e.g.,
CARL (Wang et al., 2014b), CHRF (Wang et al., 2014a), HULC
(Cui et al., 2015), linc-MD1(Legnini et al., 2014), H19(Giovarelli
et al., 2014; Tao et al., 2016)]. A very recently discovered
example of lncRNA-RNA interaction is mediated by circular
RNAs that can act as miRNA sponges [e.g., ciRS-7(Xu et al.,
2015; Geng et al., 2016; Yu et al., 2016)]. It remains to be
determined if ciRNAs can impart their function via other
mechanisms.
In addition, lncRNAs can regulate protein coding transcripts
by controlling their translation [Uchl1-as (Carrieri et al.,
2012), lincRNA-p21(Yoon et al., 2012)] or by regulating
transcript stability. For example, the lncRNA TINCR binds
Staufen 1 (Stau1) in order to stabilize mRNAs containing
the TINCR binding motif (Kretz et al., 2013). Besides
interacting with other RNA molecules, lncRNAs can also
bind to DNA, often in complex with proteins, resulting
in multi-layered regulatory complexity. Many cases of
activation or repression of genomic loci by lncRNAs have
been described to date [HOTAIR (Gupta et al., 2010), Braveheart
(Klattenhoff et al., 2013), FENDRR (Grote et al., 2013)].
In this scenario, lncRNAs recruit epigenetic modifiers to
target specific genomic loci, leading to either activation or
inactivation. LncRNAs have also been shown to regulate
gene activity co-transcriptionally, e.g., by aiding alternative
splicing of mRNA isoforms (Gonzalez et al., 2015) or binding
to newly synthesized mRNA, resulting in their stabilization
or degradation (Matsui et al., 2008; Gong and Maquat, 2011;
Wang et al., 2016a). eRNAs have been demonstrated to act
in cis to regulate expression of target (protein-coding) genes
(Ounzain et al., 2014). Another example for lncRNAs acting
in cis is during genomic imprinting, an important process
during development, where bi-allelic expression is changed
to monoallelic and viceversa. Several lncRNAs have been
demonstrated to mediate imprinting of neighboring genomic
loci [Xist & Tsix (Brown et al., 1992; Clemson et al., 1996; Lee
et al., 1999; Bell et al., 2014; Chu et al., 2015; McHugh et al.,
2015), KCNQ1OT1 (Thakur et al., 2004), Airn (Sleutels et al.,
2002)].
Recently, a handful of reports indicated that some lncRNAs
work by more conventional means than previously expected.
Several groups have independently demonstrated that a fraction
of genes currently annotated as lncRNAs can be translated
to code for short peptides (Chng et al., 2013; Pauli et al.,
2014, 2015). This also explains why some lncRNAs appear
preferentially located in the cytoplasm and in association with
ribosomes in a manner similar to typical mRNAs. In an
elegant study, Pauli et al. identified 28 candidate signaling
proteins expressed during zebrafish embryogenesis, including
toddler [(Pauli et al., 2015); also identified as ELABELA
(Chng et al., 2013)], a previously annotated lncRNA which
in reality codes for a short, conserved, secreted peptide.
Impaired expression of Toddler reduces the motility of
mesendodermal cells during zebrafish gastrulation and leads to
grave developmental defects, including cardiovascular defects.
Toddler promotes cell movement locally, suggesting that it is
neither an attractant nor a repellent, but acts as a motogen.
Toddler promotes the internalization of G-protein-coupled
APJ/Apelin receptors and activation of APJ/Apelin signaling
rescues toddler mutants. Intriguingly, toddler and similar short
peptides might constitute a previously unrecognized family of
signaling molecules crucial for vertebrate development. Recently,
the Olson lab reported another short peptide (DWORF)
translated from a previously annotated long non-coding RNA
(Nelson et al., 2016). DWORF enhances muscle contractility
by regulating Ca2+ levels in skeletal muscle cells. Based
on these studies, the genes annotated as lncRNAs should
be studied carefully to discriminate between a transcript
specific function, a function by the act of transcription or
potential peptides/novel proteins encoded by them. Taken
together, lncRNAs regulate cellular events in impressively wide
mechanistic avenues.
ROLE OF LNCRNAS IN MODULATING
CARDIAC DEVELOPMENT
In recent years, lncRNAs have been extensively studied in
both development and disease. The majority of novel lncRNAs
have been associated to carcinogenesis and cancer progression.
However, several studies have also demonstrated a crucial role
for lncRNAs in development and disease, their contribution
being particularly prominent in cardiac development and cardiac
disorders (see Table 1). These findings probably reflect more the
active efforts by the cancer and cardiac community to tackle these
prominent diseases, rather than a biological overabundance of
lncRNAs in cancer or cardiac-related cells. While thousands of
lncRNAs have been reported to be expressed exclusively in the
heart during development or disease, their function remains to
be explored (Ounzain et al., 2014, 2015b).
The heart is the first organ to form and function in
an embryo, and survival of the embryo and all subsequent
events strongly depends on its uninterrupted function. Heart
development is an extraordinarily complex process involving the
migration and integration of multiple cell lineages into a three-
dimensional organ and its adequate connection with the vascular
system (Figure 2A). Abnormalities in heart development lead
to congenital heart disease, the most common human birth
defect, which results in a series of functional defects and
a host of potentially fatal disorders, including arrhythmias,
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 November 2016 | Volume 4 | Article 128
Frank et al. A lncRNA Perspective into (Re)Building the Heart
TABLE 1 | Summary of lncRNAs involved in cardiac development and disease.
Name Species Genomic
context
Function and mechanism Location (human hg38, mouse mm10) References
ALIEN Human Intergenic Cardiovascular commitment chr20:22,560,553–22,578,642 Kurian et al., 2015
ANRIL Human Antisense Metabolism, coronary artery disease,
myocardial infarction
chr9:21994790–22121097 Yap et al., 2010; Vausort
et al., 2014
Bvht Mouse Intergenic Cardiac mesoderm commitment
Decoy
chr18:61639653–61647503 Klattenhoff et al., 2013
Carl Mouse Intergenic Mitochondria, cardiomyocyte
apoptosis; miRNA sponge
chr2:18799244–18801291 Wang et al., 2014b





Ounzain et al., 2015a
CHAST Mouse/Human Antisense Pro-hypertrophic; cis-regulation chr17:64,783,199–64,783,552 (human)
chr11:103,363,213–103,364,651 (mouse)
Viereck et al., 2016
Chrf Mouse Intergenic Cardiac hypertrophy; miRNA sponge chr18:72164057–72165898 Wang et al., 2014a




Grote et al., 2013
H19 Mouse/Human Antisense Cardiac fibroblast proliferation,
negative regulator of hypertrophy
chr11:1995176–1997835 (human)
chr7:142575532–142578146 (mouse)
Tao et al., 2016
HIF1A-AS2 Human Antisense Myocardial infarction chr14:61747039–61749089 Vausort et al., 2014
KCNQ1OT1 Human Antisense Cardiovascular development,
arrhythmia, myocardial infarction;
Guide
chr11:2,608,328–2,699,994 Thakur et al., 2004;
Korostowski et al., 2012;
Vausort et al., 2014
LIPCAR Human Unknown Heart failure chrM:7586–15887 Kumarswamy et al., 2014




Michalik et al., 2014;
Vausort et al., 2014
MEG3 Mouse/Human Intergenic Modulation of TGF-β pathway; Guide chr14:100,826,134–100,861,008 (human)
chr12:109542023–109568650 (mouse)
Mondal et al., 2015
Mhrt Mouse/Human Intergenic Cardiac hypertrophy; Decoy chr14:23,415,450–23,417,595 (human)
chr14:54,968,787–54,974,349 (mouse)
Han et al., 2014
MIAT Human Intergenic Myocardial infarction; miRNA sponge chr22:26657482–26676477 (human)
chr5:112220925–112228948 (mouse)
Yan et al., 2015
Mm67/77/
85/130/132
Mouse Intergenic Cardiac development & remodeling;
Enhancer-associated lncRNA
Cis-regulation
Several loci (see original publication) Ounzain et al., 2014
Novlncs Mouse Intergenic Cardiac remodeling;
Enhancer-associated
Several loci (see original publication) Ounzain et al., 2015b
NRF Mouse Intergenic Regulated necrosis of
cardiomyocytes; miRNA sponge
chr3:45,438,398–45,440,956 Wang et al., 2016b
PANCR Human Intergenic Cardiac differentiation chr4:110,595,513–110,615,458 Gore-Panter et al., 2016
PUNISHER Human Antisense Endothelial cell identity chr12:57,726,240–57,728,356 Kurian et al., 2015
PVT1 Mouse Antisense Cardiomyocyte cell size, possibly
regulating hypertrophy
chr15:62,037,986–62,260,212 Yu et al., 2015
RNCR3 Mouse/Human Intergenic Atheroprotective; miRNA sponge chr13:90,060,247–90,119,719 (human)
chr14:64,588,115–64,593,961 (mouse)
Shan et al., 2016
ROR Human Intergenic Pro-Hypertrophic; miRNA sponge chr18:57,054,559–57,072,119 Jiang et al., 2016
SENCR Human Antisense Smooth muscle contractility chr11:128,691,672–128,696,023 Bell et al., 2014
Smad7-
lncRNA
Mouse Antisense Enhancer-associated lncRNA,
Cis-regulation
chr18:75522879–75528680 Ounzain et al., 2014
SMILR Human Intergenic Vascular smooth muscle cell
proliferation
chr8:122,414,332–122,428,551 Ballantyne et al., 2016
TERMINATOR Human Intergenic Pluripotency, cardiovascular
development
chr1:200,411,800–200,475,513 Kurian et al., 2015
uc.167 Mouse Antisense Involved in cardiac differentiation chr5:88,889,445–89,465,982 Song et al., 2016
UCA1 Human Biomarker for acute myocardial
infarction, anti-apoptotic (rat model)
chr19:15,828,947–15,836,321 Liu et al., 2015; Yan et al.,
2016
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FIGURE 2 | Mammalian cardiac development in vivo/in vitro and consequences of aging on the heart. (A) Development of the mammalian heart is a
complex series of events, marked by distinct morphological changes. Expression of selected lncRNAs is indicated along the developmental timeline. (B) During aging,
the heart becomes hypertrophic, i.e., the heart muscle increases by an increase in cell size, not number. Furthermore, the risk of myocardial infarction (MI) increases
with age. MI can eventually result in hypertrophy in order to compensate for the loss in heart muscle. Selected lncRNAs identified to play a role in infarction or
hypertrophy are depicted.
cardiomyopathies, heart failure, and sudden death (Olson and
Schneider, 2003; Bruneau, 2008).
Due to its importance in early survival, it is not surprising
that the formation of the cardiovascular system and its function
are precisely controlled by integrated networks of transcription
factors that link signaling systems with the protein-coding
genes required for cardiac myogenesis, morphogenesis, and
contractility (Pipes et al., 2006). Surprisingly, until recently we
were unaware that these pathways are intimately intertwinedwith
dozens of critical non-coding genes, including microRNAs and
long non-coding RNAs (Pipes et al., 2006; Aguirre et al., 2014;
Kurian et al., 2015; see Table 1). These non-coding RNAs act
as fine switches to modulate and choreograph multiple aspects
of cardiac development, function, disease, and injury recovery.
The increasing number of non-coding elements identified to date
illustrates the importance of ncRNAs in modulating and creating
complex phenotypes at the cellular and organ level, especially in
the context of the heart.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 6 November 2016 | Volume 4 | Article 128
Frank et al. A lncRNA Perspective into (Re)Building the Heart
The first lncRNA identified as a critical regulator of cardiac
development was Braveheart (Klattenhoff et al., 2013). Braveheart
controls the cardiac gene network in multipotent cardiac
progenitors derived frommouse ESCs and functions upstream of
mesoderm posterior basic helix-loop-helix transcription factor 1
(MESP1), a master regulator of cardiac development. Braveheart
acts as an epigenetic regulator of cardiac commitment by
interacting with SUZ12, a member of the polycomb repressive
complex 2 (PRC2). As of now, it remains to be seen if
Braveheart is required for normal heart development in vivo.
Unfortunately, Braveheart seems to be a mouse-specific lncRNA
and no homologs have been found in other species. Its expression
is well-documented in mouse ESCs and heart samples using
RNA sequencing. However, the orthologous human and rat
genomic regions are not actively transcribed. The lack of a
Braveheart homolog in humans begs the question of how well its
knowledge will translate into the human cardiac setting. Given its
critical importance in cardiac lineage commitment, it is however
possible that an undiscovered functional Braveheart homolog
gets transcribed from a different genomic locus.
Very few lncRNAs have been functionally interrogated in vivo
in mammalian models. Fendrr, a novel lncRNA expressed in the
heart, has been explored using mouse genetics. Two independent
studies demonstrated that loss of Fendrr is embryonic lethal
in mice (Grote et al., 2013; Sauvageau et al., 2013). Mutants
display numerous developmental defects, including disrupted
cardiac morphogenesis, consistent with the finding that Fendrr
is expressed in the mouse lateral plate mesoderm and developing
hearts. However, there is a difference in the phenotype severity
associated with the two mutant mouse lines developed; while one
mutant line dies at embryonic day E13.75(Grote et al., 2013),
the other one dies postnatally (Sauvageau et al., 2013). One
possible explanation for this discrepancy is the different targeting
strategies used to remove the Fendrr gene. Mechanistically,
Fendrr has been shown to interact with the PRC2 complex to
modulate the epigenetic regulation of gene expression, andmight
be involved in the control of the activating H3K4me3 mark on a
subset of promoters, thus modifying the expression level of those
genes (Grote et al., 2013). However, the mechanisms of Fendrr-
dependent molecular events remain to be fully understood.
Embryonic stem cell (ESC) based differentiation models
provide a powerful tool for discovery and functional
identification of novel long non-coding RNAs in humans.
Current differentiation protocols allow for the precise in vitro
recapitulation of the early developmental steps leading to
cardiac commitment and cardiac or endothelial cell generation
(Kurian et al., 2013; Bhattacharya et al., 2014; Burridge et al.,
2014; Zhang et al., 2015). Using human ESCs and zebrafish as
a model of vertebrate development, we recently were able to
identify 76 novel human lncRNAs partially conserved across
vertebrates, and characterized three of them in cardiovascular
development in vertebrates (Kurian et al., 2015). These three
lncRNAs, named TERMINATOR, ALIEN [also known as
linc00261 and DEANR1(Jiang et al., 2015)] and PUNISHER, are
essential at different stages of mesodermal and cardiovascular
development, albeit their specific mechanisms of action still
remain poorly understood. TERMINATOR is an abundant
transcript in pluripotent stem cells and is essential for early
embryonic survival, pluripotency, and early mesendodermal
commitment both in zebrafish and mouse embryos. In contrast,
ALIEN is more specifically expressed in mesendodermal tissues
and its loss-of-function leads to disrupted vasculature and heart
formation. Interestingly, ALIEN is also an endodermal lncRNA
participating in pancreatic differentiation through its interaction
with FOXA2 and SMAD2/3 (Jiang et al., 2015).
REGULATION OF CARDIAC FUNCTION
AND DISEASE BY LNCRNAS IN THE ADULT
Besides their involvement in cell fate decisions and
developmental programs, lncRNAs are also important regulators
of homeostasis in the adult cardiovascular system, and their
dysregulation appears associated with a variety of disease states.
Chromatin Remodeling and Epigenetic
State Regulation by lncRNAs in the
Diseased Heart
A prominent feature of the aging or failing heart is hypertrophy,
a process involving a pathological increase in cardiomyocyte size
in order to cope with inefficient cardiac function (Figure 2B).
Two lncRNAs have been demonstrated to influence cardiac
hypertrophy in murine models. The first of them was named
Myheart (Mhrt, for myosin heavy chain-associated RNA
transcript) and constitutes a cardioprotective lncRNA cluster
transcribed antisense from the Myh7 locus in mouse (Han
et al., 2014). Mhrt is specific to cardiac tissue and highly
expressed in the heart. During pathological stress, such as
pressure overload, Mhrt expression is silenced by a chromatin
remodeling complex (Brg1-Hdac-Parp). This repression is an
essential step in the progression of dilated cardiomyopathy.
Restoring Mhrt expression to pre-stress levels is enough to
protect from disease progression and heart failure. Interestingly,
it seems that Mhrt antagonizes Brg1 (also known as Smarca4)
directly by binding to its helicase domain and preventing Brg1
recognition of its DNA targets. A human version of MHRT
exists and is repressed in cardiomyopathy cases, suggesting
the same mechanism is present in humans. Another lncRNA
involved in the same pathological process of heart remodeling
and hyperthrophy is lncRNA CHRF (cardiac hypertrophy-
related factor; Wang et al., 2014a). However, CHRF regulates
hypertrophy by very different mechanisms compared to Mhrt.
During hypertension, angiotensin-II production stimulates
paracrine and hormonal release of pro-hypertrophic factors, such
as endothelin-1 and TGF-β1. Under these conditions, microarray
profiling experiments were able to identify microRNA-489 as
a significantly downregulated transcript. Overexpression of this
microRNA was enough to attenuate the hypertrophic phenotype
in cardiomyocytes. Under cardiomyopathy conditions, lncRNA
CHRF is expressed and acts as a sponge for microRNA-
489, preventing it from exerting its function, which is
the downregulation of Myd88 (a known inducer if cardiac
hypertrophy). In another very promising recent study, the pro-
hypertrophic lncRNA CHAST was identified (Viereck et al.,
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2016). CHAST was found to be functionally conserved and
in vivo silencing of this lncRNA resulted in an improved recovery
after cardiac injury, demonstrating a potential treatment of
pathological heart remodeling processes.
Cardiac Metabolism, Mitochondrial
Function, and lncRNAs
Metabolism is an essential aspect of cellular physiology, even
more so in cardiomyocytes and the heart, an organ with
an extraordinary bio-energetic demand. Metabolic remodeling
is a hallmark of heart failure and cardiomyopathy and is
characterized by a reversion to a fetal-like glycolytic metabolism
and a capacity to efficiently employ fatty acid oxidation—the
preferred energy source for the adult heart. Very few lncRNAs
related to cardiac metabolism have been identified to date.
CARL (cardiac apoptosis-related lncRNA) is a lncRNA identified
during anoxic treatment of cardiomyocytes (Wang et al., 2014b).
During anoxia, PHB2, an important regulator of mitochondrial
fission and fusion dynamics, is strongly downregulated by
the increased expression of miR-539, leading to mitochondrial
fission and cardiomyocyte apoptosis. Interestingly, this dramatic
upregulation of miR-539 is the direct consequence of lncRNA
CARL silencing. CARL acts as a sponge for miR-539, and is
highly expressed in the heart as well as other tissues, indicating
this mechanism of apoptosis might be relevant outside the
cardiac setting. Forced overexpression of CARL is sufficient
to counter the effects of anoxia and rescue a significant
proportion of cardiomyocytes from apoptosis. The trigger for
CARL downregulation remains unknown.
Recently, a lncRNA profiling study carried out in plasma
from patients suffering from heart failure identified a number
of circulating lncRNAs associated with LV (left ventricular)
remodeling (Kumarswamy et al., 2014). The authors were
able to detect hundreds of lncRNAs, and in an interesting
turn of events, found out that the most abundant majority
of plasma lncRNAs originate from the mitochondrial genome
(77%). One lncRNA was significantly upregulated in heart failure
and predicted cardiac remodeling with high probability. This
lncRNA, named LIPCAR (for long intergenic non-coding RNA
predicting cardiac remodeling), increases significantly during
late-stage post-myocardial infarction remodeling and during
chronic heart failure, thus constituting a prognostic marker
for heart failure. The mechanisms of action of LIPCAR and
its function at the cellular and tissue level remain to be
described.
Control of Hypertension and Endothelial
Cell Dysfunction by lncRNAs
ANRIL (antisense non-coding RNA in the INK4 locus)
plays a critical role in hypertension and atherosclerosis
(Yap et al., 2010). ANRIL was discovered accidentally by
several independent genome-wide association studies (GWAS)
indicating the presence of a coronary artery disease (CAD)
risk locus in chromosome 9p21. No known protein-coding
elements were present in the haplotype block, however a
transcript of unknown function did originate and was very
active in atherosclerotic patients. Little is known about the
mechanisms by which ANRIL promotes CAD, except that
it directly regulates the expression of ADIPOR1, VAMP3,
and an orphan protein, C11ORF10. Another example of a
vascular-associated lncRNA involved in disease is MALAT1
(metastasis-associated lung adenocarcinoma transcript 1; Liu
et al., 2014; Michalik et al., 2014). MALAT1 is significantly
upregulated during hyperglycemia and appears associated with
diabetes mellitus and microvascular endothelial cell dysfunction.
MALAT1 knockdown restores vessel function and alleviates
inflammation in diabetic rats (Liu et al., 2014). Upon further
inspection, it was found that MALAT1 accumulates in the
nucleus of endothelial cells, and it is necessary for cell survival,
migration, and angiogenesis in a similar fashion to lncRNA
PUNISHER, as described before.
TRANSLATIONAL STRATEGIES
Although much remains to be learned about lncRNA biology
and their mechanisms of gene regulation, lncRNAs are
quickly emerging as interesting therapeutic targets in a very
similar fashion to their other non-coding relatives, microRNAs.
MicroRNAs have been the focus of intense translational and
clinical research in the last decade due to their therapeutic
promise, and a few successful examples exist and/or are
close to commercialization (Kole et al., 2012; Sharma et al.,
2014; Lundin et al., 2015). Most approaches are based on
specific silencing of microRNA expression using short antisense
oligonucleotides (ASOs) with patented derivatives resistant to
cellular degradation. ASOs work on similar principles as those
of microRNA-mRNA binding and degradation (Walder and
Walder, 1988; Dagle et al., 1990; Braasch et al., 2002; Kurreck
et al., 2002; Grünweller et al., 2003). ASOs are exciting in
the context of lncRNA therapeutics because the same validated
approaches as those tested for microRNAs are applicable. As
a matter of fact, many of the reports described in this review
have made use of ASOs to knockdown lncRNAs successfully for
functional studies in mice or rats, bringing lncRNA therapeutics
one step closer to the clinic. Overexpression of cardioprotective
or otherwise beneficial lncRNAs is a much more complicated
matter, given the length of these molecules. Efficient delivery
would be complicated by the inability of the long modified
transcript to cross the membrane barrier, not to mention
synthesis costs and potential toxicity. As of now, alternatives
would include the use of gene delivery vectors, such as
engineered adeno-associated virus (AAVs), to provide exogenous
expression of the desired gene (Asokan et al., 2012; Kotterman
and Schaffer, 2014; Samulski and Muzyczka, 2014). Numerous
clinical trials using gene therapies are underway (Ginn et al.,
2013) and the European Commission already approved its first
gene therapy [targeting lipoprotein lipase deficiency (LPLD)]
in 2012. Additionally, the first gene therapy for children [for
treatment of severe combined immunodeficiency (ADA-SCID)]
was very recently approved in by the European commission. Thus
therapeutic strategies aimed at lncRNA overexpression might be
closer than expected.
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CONCLUSIONS AND FUTURE
PROSPECTS
Non-coding RNAs have emerged as critical regulators of
gene expression and function. Understanding their molecular
mechanisms of action is providing important novel insights into
(cardiac) development, homeostasis, and disease. Judging from
the number of predicted lncRNA genes, it is conceivable that
future studies will clarify their role and expand our knowledge
on the regulatory networks underlying cardiac development
and disease. Eventually, these advances will translate into
novel therapeutic approaches targeting the leading cause of
death, and thus providing a substantial benefit to human
healthcare.
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